These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2167352)

  • 1. Comparative studies of HSV-1 antigens solubilised from infected cells by using non-ionic or zwitterionic detergents.
    Jennings R; Erturk M
    J Med Virol; 1990 Jun; 31(2):98-108. PubMed ID: 2167352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zwitterionic detergent solubilisation of HSV-1 surface antigens.
    Jennings R; Quasim T; Sharrard RM; Hockley D; Potter CW
    Arch Virol; 1988; 98(3-4):137-53. PubMed ID: 2831853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment.
    Mukhlis FA; Jennings R; Stephenson TJ; Quasim T; Potter CW
    Vaccine; 1986 Sep; 4(3):191-6. PubMed ID: 3020821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
    Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
    Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.
    al-Ghamdi A; Jennings R; Bentley H; Potter CW
    Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
    Ertürk M; Jennings R; Hockley D; Potter CW
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL; Duncan BE; Raybould TJ; Watson DH
    J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH; Oakes JE; Lausch RN
    Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.
    Rosenthal KL; Smiley JR; South S; Johnson DC
    J Virol; 1987 Aug; 61(8):2438-47. PubMed ID: 3037106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.
    Bröker M; Abel KJ; Köhler R; Hilfenhaus J; Amann E
    Med Microbiol Immunol; 1990; 179(3):145-59. PubMed ID: 2169577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 16. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL
    Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.
    Ghiasi H; Nesburn AB; Wechsler SL
    Vaccine; 1996 Feb; 14(2):107-12. PubMed ID: 8852405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Envelope and membrane glycoproteins of Herpes simplex virus].
    Ramos-Kuri JM
    Rev Latinoam Microbiol; 1992; 34(1):23-31. PubMed ID: 1345300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.